(Q35612327)

9 August 2017

1 reference

title

Aromatase inhibitors for chemoprevention (English)

1 reference

9 August 2017

author

Kathrin Strasser-Weippl

series ordinal

2

object named as

Kathrin Strasser-Weippl

1 reference

9 August 2017

Paul E Goss

1

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Best Practice and Research: Clinical Endocrinology and Metabolism

9 August 2017

published in

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

113-130

1 reference

Recent trends in U.S. breast cancer incidence, survival, and mortality rates

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Characteristics that predict risk of breast cancer before and after the menopause

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Body size in different periods of life and breast cancer risk in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

A prospective study of endogenous estrogens and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Estrogen Metabolism and Excretion in Oriental and Caucasian Women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Postmenopausal estrogen use and invasive versus in situ breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

A cohort study of oral contraceptive use and risk of benign breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Oral contraceptives and the risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Dietary phytoestrogens and cancer: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

A rare CYP19 (aromatase) variant may increase the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Neoplastic transformation of cultured mammalian cells by estrogens and estrogenlike chemicals

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

17Beta-estradiol is carcinogenic in human breast epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Carcinogenicity of catechol estrogens in Syrian hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

DNA adduct formation in liver and kidney of male Syrian hamsters treated with estrogen and/or alpha-naphthoflavone.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aberrant expression of aromatase in breast cancer tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

The importance of local synthesis of estrogen within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Regulation of aromatase activity within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase inhibitors and their antitumor effects in model systems

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary gl

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Characterization of a novel silencer element in the human aromatase gene PII promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Tamoxifen for breast cancer among hysterectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase inhibitors--mechanisms of steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase inhibitors--mechanisms for non-steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

SERMs: current status and future trends

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2803%2900070-8

7 January 2021

10.1016/S1521-690X(03)00070-8

Identifiers

DOI

1 reference

9 August 2017

1 reference